The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI
Open accessAbstract
Tissue inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for risk stratification in AKI. However, the association of urinary TIMP-2 and IGFBP7 with long-term outcomes is unknown. We evaluated the 9-month incidence of a composite end point of all-cause mortality or the need for RRT in a secondary analysis of a prospective observational international study of critically ill adults. Two predefined [TIMP-2]⋅[IGFBP7] cutoffs (0.3 for high sensitivity and 2.0 for high specificity) for the development of AKI were evaluated. Cox proportional hazards models were used to determine risk for the composite end point. Baseline [TIMP-2]⋅[IGFBP7] values were available for 692 subjects, of whom 382 (55.2%) subjects developed stage 1 AKI (defined by Kidney Disease Improving Global Outcomes guidelines) within 72 hours of enrollment and 217 (31.4%) subjects met the composite end point. Univariate analysis showed that [TIMP-2]⋅[IGFBP7]>2.0 was associated with increased risk of the composite end point (hazard ratio [HR], 2.11; 95% confidence interval [95% CI], 1.37 to 3.23; P<0.001). In a multivariate analysis adjusted for the clinical model, [TIMP-2]⋅[IGFBP7] levels>0.3 were associated with death or RRT only in subjects who developed AKI (compared with levels≤0.3: HR, 1.44; 95% CI, 1.00 to 2.06 for levels>0.3 to ≤2.0; P=0.05 and HR, 2.16; 95% CI, 1.32 to 3.53 for levels>2.0; P=0.002). In conclusion, [TIMP-2]⋅[IGFBP7] measured early in the setting of critical illness may identify patients with AKI at increased risk for mortality or receipt of RRT over the next 9 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
Self-citationWajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903
Proinflammatory actions of angiotensins
Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Rupérez, M., & Egido, J. (2001) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200105000-00005 · Cited by 412
Severino, V, Alessio, N., Farina, A., Sandomenico, A., Cipollaro, M., Peluso, G., Galderisi, U., & Chambery, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.445 · Cited by 214
IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways
Benatar, T., Yang, W., Amemiya, Y., Evdokimova, V., Kahn, H., Holloway, C., & Seth, A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1816-4 · Cited by 89
Zuo, S., Liu, C., Wang, J., Wang, F., Xu, W., Cui, S., Yuan, L., Chen, X., Fan, W., Cui, M., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1153-y · Cited by 58
Cited by
Kellum, J. A., Romagnani, P., Ashuntantang, G., Ronco, C., Zarbock, A., & Anders, H.-J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00284-z · Cited by 1,741
Self-citationMeersch, M., Schmidt, C., Hoffmeier, A., Van Aken, H., Wempe, C., Gerss, J., & Zarbock, A. (2017) · Intensive Care Medicine · doi:10.1007/s00134-016-4670-3 · Cited by 892
Ostermann, M., Zarbock, A., Goldstein, S., Kashani, K., Macedo, E., Murugan, R., Bell, M., Forni, L., Guzzi, L., Joannidis, M., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19209 · Cited by 677
Self-citationCalzavacca, P., Licari, E., & Bellomo, R. (2010) · Surgical Intensive Care Medicine · doi:10.1007/978-0-387-77893-8_38 · Cited by 533
Paradigms of acute kidney injury in the intensive care setting
Kellum, J. A., & Prowle, J. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.184 · Cited by 419
Self-citation
Metadata
- Authors
- Koyner, J. L., Shaw, A. D., Chawla, L. S., Hoste, E. A. J., Bihorac, A., Kashani, K., Haase, M., Shi, J., & Kellum, J. A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2015-07
- Volume
- 26
- Issue
- 7
- Pages
- 1747-1754
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2171175193
- Cited by
- 231
- References
- 7
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. https://app.cochat.ai/papers/10.1681/asn.2014060556
- The paper
- Koyner, J. L., Shaw, A. D., Chawla, L. S., Hoste, E. A. J., Bihorac, A., Kashani, K., Haase, M., Shi, J., & Kellum, J. A. (2015). Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014060556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.